IL264674B2 - Antibodies to siglec7 for cancer treatment - Google Patents

Antibodies to siglec7 for cancer treatment

Info

Publication number
IL264674B2
IL264674B2 IL264674A IL26467419A IL264674B2 IL 264674 B2 IL264674 B2 IL 264674B2 IL 264674 A IL264674 A IL 264674A IL 26467419 A IL26467419 A IL 26467419A IL 264674 B2 IL264674 B2 IL 264674B2
Authority
IL
Israel
Prior art keywords
seq
antibody
sequence
variable region
chain variable
Prior art date
Application number
IL264674A
Other languages
English (en)
Hebrew (he)
Other versions
IL264674B1 (en
IL264674A (https=
Inventor
Korver Wouter
Bebbington Christopher
Tomasevic Nenad
EL BADER Suzy
Luehrsen Kenneth
Original Assignee
Allakos Inc
Korver Wouter
Bebbington Christopher
Tomasevic Nenad
EL BADER Suzy
Luehrsen Kenneth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allakos Inc, Korver Wouter, Bebbington Christopher, Tomasevic Nenad, EL BADER Suzy, Luehrsen Kenneth filed Critical Allakos Inc
Publication of IL264674A publication Critical patent/IL264674A/en
Publication of IL264674B1 publication Critical patent/IL264674B1/en
Publication of IL264674B2 publication Critical patent/IL264674B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL264674A 2016-08-05 2017-08-04 Antibodies to siglec7 for cancer treatment IL264674B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662371680P 2016-08-05 2016-08-05
PCT/US2017/045641 WO2018027203A1 (en) 2016-08-05 2017-08-04 Anti-siglec-7 antibodies for the treatment of cancer

Publications (3)

Publication Number Publication Date
IL264674A IL264674A (https=) 2019-03-31
IL264674B1 IL264674B1 (en) 2023-05-01
IL264674B2 true IL264674B2 (en) 2023-09-01

Family

ID=61073084

Family Applications (1)

Application Number Title Priority Date Filing Date
IL264674A IL264674B2 (en) 2016-08-05 2017-08-04 Antibodies to siglec7 for cancer treatment

Country Status (13)

Country Link
US (1) US11773162B2 (https=)
EP (1) EP3494142A4 (https=)
JP (1) JP7137563B2 (https=)
KR (1) KR20190035863A (https=)
CN (1) CN109790223A (https=)
AU (1) AU2017307616A1 (https=)
BR (1) BR112019002331A2 (https=)
CA (1) CA3032437A1 (https=)
EA (1) EA201990296A1 (https=)
IL (1) IL264674B2 (https=)
MX (1) MX2019001471A (https=)
SG (1) SG11201901020RA (https=)
WO (1) WO2018027203A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
BR112019002331A2 (pt) 2016-08-05 2019-06-18 Allakos Inc anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
US11447545B2 (en) 2017-07-10 2022-09-20 Innate Pharma Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US11912766B2 (en) * 2018-01-11 2024-02-27 Allakos, Inc. Anti-Siglec-7 antibodies having reduced effector function
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021247821A1 (en) * 2020-06-03 2021-12-09 The Wistar Institute Of Anatomy And Biology Monoclonal antibodies against human siglec-9 and use thereof for immunotherapy
KR20230035576A (ko) 2020-07-07 2023-03-14 비온테크 에스이 Hpv 양성 암 치료용 rna
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
JP2026501506A (ja) 2022-12-14 2026-01-16 アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
JP2025027841A (ja) * 2023-08-17 2025-02-28 国立大学法人 東京大学 ＶＳＩＧ４とＳｉｇｌｅｃ－７との分子間相互作用に対する抗ＶＳＩＧ４、抗Ｓｉｇｌｅｃ－７阻害抗体
TW202541837A (zh) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016038064A1 (en) * 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20070244038A1 (en) 2006-04-12 2007-10-18 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
EP2172483A4 (en) * 2007-07-04 2010-08-04 Forerunner Pharma Res Co Ltd ANTI-MUC17 ANTIBODY
BR112014020826A8 (pt) 2012-02-24 2017-09-19 Stem Centrx Inc Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
ES2791183T3 (es) * 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anticuerpos anti-GDF15
WO2014188423A1 (en) * 2013-05-21 2014-11-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mast cell related pathologies
MX383594B (es) 2014-08-07 2025-03-14 Daiichi Sankyo Co Ltd Anticuerpo anti-orai1.
KR20180054639A (ko) * 2015-08-28 2018-05-24 알렉터 엘엘씨 항-siglec-7 항체 및 이의 사용 방법
AU2017207807A1 (en) 2016-01-12 2018-07-12 Palleon Pharmaceuticals Inc. Use of Siglec-7 or Siglec-9 antibodies for the treatment of cancer
EP3426688A1 (en) * 2016-03-08 2019-01-16 Innate Pharma Siglec neutralizing antibodies
BR112019002331A2 (pt) 2016-08-05 2019-06-18 Allakos Inc anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016038064A1 (en) * 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HUDAK, JASON E., STEPHEN M. CANHAM, AND CAROLYN R. BERTOZZI., GLYCOCALYX ENGINEERING REVEALS A SIGLEC-BASED MECHANISM FOR NK CELL IMMUNOEVASION., 1 January 2014 (2014-01-01) *
JANDUS, CAMILLA, ET AL., INTERACTIONS BETWEEN SIGLEC-7/9 RECEPTORS AND LIGANDS INFLUENCE NK CELL–DEPENDENT TUMOR IMMUNOSURVEILLANCE., 24 February 2014 (2014-02-24) *
KAWASAKI, NORIHITO, ET AL., TARGETED DELIVERY OF MYCOBACTERIAL ANTIGENS TO HUMAN DENDRITIC CELLS VIA SIGLEC-7 INDUCES ROBUST T CELL ACTIVATION., 7 July 2014 (2014-07-07) *
MITSUKI, MOTOAKI, ET AL., SIGLEC-7 MEDIATES NONAPOPTOTIC CELL DEATH INDEPENDENTLY OF ITS IMMUNORECEPTOR TYROSINE-BASED INHIBITORY MOTIFS IN MONOCYTIC CELL LINE U937., 1 March 2010 (2010-03-01) *
NICOLL, GAVIN, ET AL., IDENTIFICATION AND CHARACTERIZATION OF A NOVEL SIGLEC, SIGLEC-7, EXPRESSED BY HUMAN NATURAL KILLER CELLS AND MONOCYTES., 26 November 1999 (1999-11-26) *
VARCHETTA, STEFANIA, ET AL., ENGAGEMENT OF SIGLEC-7 RECEPTOR INDUCES A PRO-INFLAMMATORY RESPONSE SELECTIVELY IN MONOCYTES., 28 September 2012 (2012-09-28) *
VARCHETTA, STEFANIA, ET AL., SIALIC ACID-BINDING IG-LIKE LECTIN-7 INTERACTS WITH HIV-1 GP120 AND FACILITATES INFECTION OF CD4POST CELLS AND MACROPHAGES., 13 December 2013 (2013-12-13) *

Also Published As

Publication number Publication date
EP3494142A4 (en) 2020-04-01
US11773162B2 (en) 2023-10-03
IL264674B1 (en) 2023-05-01
WO2018027203A1 (en) 2018-02-08
MX2019001471A (es) 2019-10-30
JP2019526622A (ja) 2019-09-19
KR20190035863A (ko) 2019-04-03
EA201990296A1 (ru) 2019-08-30
US20190194323A1 (en) 2019-06-27
SG11201901020RA (en) 2019-03-28
CN109790223A (zh) 2019-05-21
JP7137563B2 (ja) 2022-09-14
BR112019002331A2 (pt) 2019-06-18
IL264674A (https=) 2019-03-31
CA3032437A1 (en) 2018-02-08
EP3494142A1 (en) 2019-06-12
AU2017307616A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
US11773162B2 (en) Anti-Siglec-7 antibodies for the treatment of cancer
WO2021247591A1 (en) Antibodies to tigit
AU2019274654B2 (en) Antibodies specific for CD3 and uses thereof
IL296874A (en) Antibodies specific for the human poliovirus receptor
US11912766B2 (en) Anti-Siglec-7 antibodies having reduced effector function
WO2021139682A1 (en) Anti-galectin-9 antibody and uses thereof
WO2021141907A1 (en) Anti-tnfr2 antibody and uses thereof
CA3224693A1 (en) Anti-tnfr2 antibody and uses thereof
WO2023091512A2 (en) Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
HK40060175B (zh) 特异性针对人类连接蛋白-2的抗体
HK40001896A (en) Antibodies specific to human poliovirus receptor (pvr)
HK40001896B (en) Antibodies specific to human poliovirus receptor (pvr)